24 completed, 11 unknown, 3 terminated, 1 recruiting. 39 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 39 | Completed 24, Unknown 11, Terminated 3, Recruiting 1 |
Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment Canagliflozin group, Sitagliptin, Acarbose - Type 2 Diabetes Mellitus, Cognitive Impairment | Phase 4 | Recruiting | Fudan University | 60 | 2024-08-19 | 2026-07-17 |
| The Efficacy and Tolerability of Acarbose in Healthy Individuals Acarbose Tablets 50mg - Tolerance, Side Effect | Phase 4 | Completed | AgelessRx | 15 | 2022-08-10 | 2023-07-27 |
| Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus | Phase 4 | Unknown | Peking Union Medical College Hospital | 180 | 2020-03-02 | 2020-02-27 |
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive Alogliptin, Acarbose, Metformin - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 1293 | 2019-06-29 | 2022-04-25 |
| Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Sitagliptin, Acarbose - Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 | Phase 4 | Unknown | Chinese PLA General Hospital | 300 | 2018-10-01 | 2018-07-27 |
| Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30 - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 384 | 2018-01-20 | 2022-04-25 |
| Research of Intensive Metabolic Intervention Before Pregnancy in PCOS Acarbose 100 MG, Exenatide, Orlistat - PCOS, Impaired Glucose Tolerance | Phase 4 | Unknown | RenJi Hospital | 160 | 2018-01-01 | 2017-12-26 |
| A Phase IV Study in Drug-Naive Patients With T2DM in China Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus | Phase 4 | Terminated | AstraZeneca | 304 | 2017-12-15 | 2021-12-07 |
| Human Oral Detection of Glucose Olygomers Acarbose - Healthy Volunteers | Phase 4 | Completed | Oregon State University | 157 | 2017-04-21 | 2023-02-21 |
| Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) INSULIN GLARGINE, metformin, acarbose - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Sanofi | 892 | 2016-09-09 | 2022-04-25 |
| Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Acarbose, Vildagliptin - Diabetes Mellitus, Type 2, Obesity | Phase 4 | Unknown | Peking University | 100 | 2016-03-01 | 2016-12-21 |
| Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Acarbose, Metformin, Saxagliptin - Type 2 Diabetes Mellitus | Phase 4 | Unknown | Fifth Affiliated Hospital, Sun Yat-Sen University | 100 | 2015-12-01 | 2015-11-18 |
| Treatment of Hypoglycemia Following Gastric Bypass Surgery Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity | Phase 4 | Completed | Zealand University Hospital | 11 | 2015-10-01 | 2018-03-07 |
| the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin premix insulin, metformin, Acarbose - Type 2 Diabetes | Phase 4 | Unknown | Shanghai 6th People's Hospital | 80 | 2014-12-01 | 2015-05-08 |
| Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients Gemigliptin, Acarbose - Endothelial Function, Type 2 Diabetes | Phase 4 | Unknown | Seoul National University Hospital | 54 | 2014-09-01 | 2015-07-16 |
| 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy Saxagliptin, Acarbose - Type 2 Diabetes Mellitus | Phase 4 | Completed | AstraZeneca | 689 | 2014-09-01 | 2017-04-14 |
| Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes Metformin, Voglibose, Acarbose - Type 2 Diabetes Mellitus | Phase 4 | Completed | Takeda | 494 | 2014-05-09 | 2019-03-13 |
| Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus Mitiglinide, Acarbose - Type 2 Diabetes Mellitus | Phase 4 | Completed | Zhongda Hospital | 248 | 2014-05-01 | 2016-07-14 |
| A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Glimepiride, Metformin, Pioglitazone - Diabetes Mellitus, Type 2 | Phase 4 | Terminated | Eli Lilly and Company | 192 | 2014-02-01 | 2019-10-09 |
| Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease Sitagliptin and acarbose - Newly Diagnosed Type 2 Diabetes, Coronary Artery Disease | Phase 4 | Completed | Wuhan General Hospital of Guangzhou Military Command | 66 | 2013-07-01 | 2015-08-18 |
Showing 20 of 39. Sign in to see all of them.
Diabetes Mellitus, Type 2 (27) · Diabetes Mellitus (6) · Glucose Intolerance (5) · Coronary Artery Disease (2) · Hyperglycemia (2) · Insulin Resistance (2) · Obesity (2) · Acute Coronary Syndrome (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Coronary Disease (1) · Dyslipidemias (1) · Hepatitis C, Chronic (1) · Hypoglycemia (1) · Kidney Diseases (1)
Sanofi (3) · AstraZeneca (2) · Novartis Pharmaceuticals (2) · AgelessRx (1) · Aichi Gakuin University (1) · Bayer (1) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Fudan University (1) · Indiana University (1) · Inje University (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Karolinska Institutet (1) · Merck Sharp & Dohme LLC (1)
China (18) · United States (5) · South Korea (4) · Taiwan (3) · Austria (1) · Canada (1) · Germany (1) · Hong Kong (1) · Iran (1) · Japan (1) · Mexico (1) · Puerto Rico (1) · Sweden (1) · United Kingdom (1)
Ashraf Moini, MD (1) · Bita Eslami, MPH (1) · Caroline C Gormsen, M.D. (1) · Elham Amirchaghmaghi, MD (1) · Guang Ning, M.D. Ph.D. (1) · Harn-Shen Chen, MD, PhD (1) · Hertzel Gerstein, MD (1) · Jeonghyun Park, MD PhD (1)
PMID 16112958, PMID 16801564, PMID 16936159, PMID 19515542, PMID 19656312, PMID 21376417, PMID 22078152, PMID 23602502, PMID 23631607, PMID 24030946, PMID 24431911, PMID 24819707, PMID 24932223, PMID 25781235, PMID 27533307, PMID 27812149, PMID 28271251, PMID 28296055, PMID 28324049, PMID 28671753, PMID 28917545, PMID 29873004, PMID 31907828, PMID 32130661, PMID 32641379, PMID 33035598, PMID 34286454, PMID 35930018, PMID 36273168, PMID 40270326, PMID 40395816
K23DK074439 (1)